Currently, therapeutic angiogenesis via direct delivery of growth factors has shown great promise in animal models, but has not been successful in humans thus far. Therefore, continuing search for effective therapeutic approaches aimed at promoting myocardial angiogenesis is desperately needed. Our recent work interestingly showed that Hsp20-overexpressing cardiomyocytes (Hsp20-myocytes) possessed pro- angiogenic capacity, which was associated with increased secretion of exosomes, a group of naturally occurring nano-vesicles (30-100nm) actively released from cells. In addition, our latest data showed that: 1) exosomes derived from Hsp20-myocytes, but not from Hsp20-knockdown myocytes, contained a large amount of Hsp20, VEGFR2 and p-Akt, which were efficiently transferred into endothelial cells, resulting in activation of the pro-angiogenic signaling pathway;2) Hsp20 interacted with Tsg101, a protein known to be involved in exosome biogenesis;and 3) knockdown of Tsg101 by siRNA attenuated exosome secretion from Hsp20-myocytes. Thus, it will be very important to test whether exosome quantity (Tsg101-dependent exosome biogenesis) or quality (Hsp20-reprogrammed exosomes) is critical for Hsp20-myocyte-elicited pro- angiogenesis. We hypothesize that exosomes and Hsp20 are both required for cardiomyocyte-catalyzed angiogenesis, and that Hsp20-reprogrammed exosomes have therapeutic benefits to diabetic animal hearts, which exhibit an impaired post-ischemic angiogenesis and microvascular rarefaction. These hypotheses will be tested by pursuing three specific aims: 1) Determine whether exosomes are essential for Hsp20- myocyte-induced angiogenesis. Currently, we are generating a mouse model with cardiac-specific deletion of Tsg101 to inhibit exosome production. This model will be crossed with Hsp20-transgenic mice for testing whether Hsp20-myocyte-elicited pro-angiogenic effects are attenuated by blockade of exosome generation. 2) Determine whether Hsp20 is required for exosome-mediated myocardial angiogenesis. We are creating an inducible mouse model with cardiac-specific deletion of Hsp20 to test whether Hsp20 plays an essential role in reprogramming pro-angiogenic exosomes. 3) Test whether Hsp20-stem cell- derived exosomes improve angiogenesis in diabetic animal hearts. We propose to use bone marrow- derived mesenchymal stem cells as a therapeutic source of Hsp20-reprogrammed exosomes, because they are more readily obtained than cardiomyocytes. We will use streptozotocin (STZ)-induced diabetic rats and the Goto-Kakizaki (GK) rats, two well-established diabetic animal models, to pursue this translational research. Together, the proposed studies are expected to unveil a previously unrecognized role of Hsp20 in exosomal reprogramming and in the promotion of cardiomyocyte-induced angiogenesis. Additionally, it is expected to provide novel insights that lead to the development of original exosome-based therapeutic strategies for the treatment of coronary artery disease.

Public Health Relevance

Coronary artery disease (CAD) remains the leading cause of morbidity and mortality in the United States. The proposed research is relevant to public health because the elucidation of cardiomyocyte-derived exosomes and Hsp20-reprogrammed exosomes in myocardial angiogenesis is ultimately expected to open new avenues and develop novel therapeutic tools for transferring those beneficial proteins into the diseased heart, thereby resulting in an improved angiogenesis and contractile function. Thus, the proposed project is relevant to the part of NIH's mission that pertains to advancing fundamental knowledge and translational study that will help to reduce the burdens of human disability.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL087861-06
Application #
8577869
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Schwartz, Lisa
Project Start
2007-04-18
Project End
2018-06-30
Budget Start
2013-07-26
Budget End
2014-06-30
Support Year
6
Fiscal Year
2013
Total Cost
$377,230
Indirect Cost
$139,230
Name
University of Cincinnati
Department
Pharmacology
Type
Schools of Medicine
DUNS #
041064767
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Yue, X; Yang, X; Lin, X et al. (2014) Rnd3 haploinsufficient mice are predisposed to hemodynamic stress and develop apoptotic cardiomyopathy with heart failure. Cell Death Dis 5:e1284
Wang, Xiaohong; Huang, Wei; Yang, Yang et al. (2014) Loss of duplexmiR-223 (5p and 3p) aggravates myocardial depression and mortality in polymicrobial sepsis. Biochim Biophys Acta 1842:701-11
Wang, Xiaohong; Huang, Wei; Liu, Guansheng et al. (2014) Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. J Mol Cell Cardiol 74:139-50
Essandoh, Kobina; Fan, Guo-Chang (2014) Role of extracellular and intracellular microRNAs in sepsis. Biochim Biophys Acta 1842:2155-2162
Wen, Zhili; Huang, Wei; Feng, Yuliang et al. (2014) MicroRNA-377 regulates mesenchymal stem cell-induced angiogenesis in ischemic hearts by targeting VEGF. PLoS One 9:e104666
Zuo, Shi; Jones, W Keith; Li, Hongxia et al. (2012) Paracrine effect of Wnt11-overexpressing mesenchymal stem cells on ischemic injury. Stem Cells Dev 21:598-608
Zhu, Hongyan; Fan, Guo-Chang (2012) Role of microRNAs in the reperfused myocardium towards post-infarct remodelling. Cardiovasc Res 94:284-92
Huang, Wei; Wang, Tao; Zhang, Dongsheng et al. (2012) Mesenchymal stem cells overexpressing CXCR4 attenuate remodeling of postmyocardial infarction by releasing matrix metalloproteinase-9. Stem Cells Dev 21:778-89
Wang, Xiaohong; Zhu, Hongyan; Zhang, Xiaowei et al. (2012) Loss of the miR-144/451 cluster impairs ischaemic preconditioning-mediated cardioprotection by targeting Rac-1. Cardiovasc Res 94:379-90
Zhang, Xiaowei; Wang, Xiaohong; Zhu, Hongyan et al. (2012) Hsp20 functions as a novel cardiokine in promoting angiogenesis via activation of VEGFR2. PLoS One 7:e32765

Showing the most recent 10 out of 26 publications